Biogen Inc (BUE:BIIB)
ARS 18636 201.5 (1.09%) Market Cap: 28.98 Til Enterprise Value: 34.17 Til PE Ratio: 28.13 PB Ratio: 2.14 GF Score: 49/100

Q4 2019 Sangamo Therapeutics Inc Earnings and Collaboration Agreement with Biogen Inc Call Transcript

Feb 28, 2020 / 01:00PM GMT
Operator

Good morning, and welcome to the Sangamo Therapeutics Teleconference to discuss Fourth Quarter 2019 Financial Results. This call is being recorded. I will now pass you over to the coordinator of this event, McDavid Stilwell, Senior Vice President of Corporate Communication and Investor Relations.

McDavid Stilwell
Sangamo Therapeutics, Inc. - SVP of Corporate Communications & IR

Thank you for joining us today. Yesterday afternoon, we issued a press release announcing a global collaboration, and earlier this morning, we issued fourth quarter and full year 2019 results. During our call today, we'll be referencing slides from our corporate presentation, which can be found at our website, sangamo.com, under the Investors + Media section in the Events + Presentations page.

This call includes forward-looking statements. These statements include, but are not limited to, the timing and scope of Sangamo's genomic medicine platform and products, the potential for Sangamo's product candidates to provide clinical benefit to patients, Sangamo's collaborations

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot